⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IRWD News
Ironwood Pharmaceuticals, Inc. - Class A
Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight
prnewswire.com
CYTK
NVO
BCDA
AZN
BMY
LLY
MESO
ASMB
LXRX
VTRS
AMGN
IRWD
NVS
MRK
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
businesswire.com
IRWD
Form 8-K
sec.gov
IRWD
Form 8-K
sec.gov
IRWD
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
businesswire.com
IRWD
Form 8-K/A
sec.gov
IRWD
Form 8-K
sec.gov
IRWD
Form 8-K
sec.gov
IRWD
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
businesswire.com
IRWD
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
businesswire.com
IRWD